ARTICLE | Finance
Jeito joins NMD’s syndicate to help Danish play build clinical, U.S. strategy
The French VC attracted by NMD’s ability to identify patients with severe neuromuscular disease likely to respond to therapy
February 23, 2022 12:24 AM UTC
The addition of Jeito to a syndicate of leading European VCs backing Danish start-up NMD brings clinical expertise and an ability to build a U.S. presence to the neuromuscular disorders play as it looks to the complete Phase IIa testing for its potentially first-in-class myasthenia gravis therapy.
NMD Pharma A/S raised €35 million ($39.6 million) in a series B round on Feb. 15 to advance its portfolio of small molecule CLC1 inhibitors for severe neuromuscular disorders. ...
BCIQ Target Profiles